Related Experiment Video
Updated: Jun 10, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related
Naveen C Srivastav1, Dinesh Rai, Christopher Tse
1Department of Laboratory Medicine and Pathology, 1-71 Medical Sciences Building, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Abstract:
Tuberculosis (TB) has become an increasing problem since the emergence of human immunodeficiency virus and increasing appearance of drug-resistant strains. There is an urgent need to advance our knowledge and discover a new class of agents that are distinct than current therapies. Antimycobacterial activities of several 5-alkyl, 5-alkynyl, furanopyrimidines and related 2'-deoxynucleosides were investigated against Mycobacterium tuberculosis. Compounds with 5-arylalkynyl substituents (23-26, 33, 35) displayed potent in vitro antitubercular activity against Mycobacterium bovis and Mycobacterium tuberculosis. The in vivo activity of 5-(2-pyridylethynyl)-uracil (26) and its 2'-deoxycytidine analogue, 5-(2-pyridylethynyl)-2'-deoxycytidine (35), was assessed in BALB/c mice infected with M. tuberculosis (H37Ra). Both compounds 26 and 35 given at a dose of 50 mg/kg for 5 weeks showed promising in vivo efficacy in a mouse model, with the 2'-deoxycytidine derivative being more effective than the uracil analogue and a reference drug d-cycloserine. These data indicated that there is a significant potential in this class of compounds.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Viral Protein Synthesis
Biosynthesis of Nucleic Acids
Drugs that Destabilize Microtubules

